+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Forecast 2024-2030- Product Image
Global Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Forecast 2024-2030- Product Image
Sale

Global Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Forecast 2024-2030

  • PDF Icon

    Report

  • 197 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5666022
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cardiovascular Drugs Market size was estimated at USD 82.65 billion in 2023, USD 90.13 billion in 2024, and is expected to grow at a CAGR of 9.15% to reach USD 152.61 billion by 2030.

Cardiovascular drugs encompass the range of medications prescribed for the treatment of heart diseases and related circulatory problems. This includes a variety of therapeutic drug classes, such as antihypertensives, anticoagulants, antiarrhythmics, antianginals, and cholesterol-lowering drugs. These medications are primarily used in the clinical management of conditions such as hypertension, hyperlipidemia, coronary artery disease, arrhythmias, and heart failure. The increasing incidence of cardiovascular conditions globally, especially among the aging population, is expanding the need for cardiovascular drugs. Rising healthcare spending and improvements in healthcare infrastructure in emerging economies are propelling market expansion. Adverse drug reactions and safety concerns lead to product recalls and tarnish the brand image, subsequently impacting the market growth. New advances in personalized medicine and biologics are presenting significant opportunities in the cardiovascular drug market. Additionally, rising research & development activities to introduce novel cardiovascular are expected to fuel the market growth.

Regional Insights

The Americas maintain a significant position in the global cardiovascular drugs market because of high healthcare expenditure, sophisticated healthcare infrastructure, and significant research and development activities. The U.S. market exhibits strong demand for innovative and branded drugs bolstered by a consumer base that prioritizes efficacy and brand reputation. The European Union (EU) countries exhibit a strong demand for cardiovascular drugs with a large aging population. Market dynamics in the EU are shaped by rigorous regulations and the presence of numerous global pharmaceutical players. There is a mix of preference for brand-name drugs and generics driven by cost-containment measures within various healthcare systems. In the Middle East and Africa, the market for cardiovascular drugs is evolving with rising incidence rates of heart diseases. The Asia Pacific region is rapidly emerging as a significant market for cardiovascular drugs, driven by a growing aging population and an increasing prevalence of cardiovascular diseases (CVDs). In this region, China and India are significant countries due to their large populations and the burgeoning incidence of CVDs. In terms of consumer needs, access to affordable healthcare and generic medicine is paramount due to diverse economic strata across the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cardiovascular Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiovascular Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apotex Inc., AstraZeneca PLC, Auro Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Chiesi USA, Inc., Cipla Limited, Cornerstone Therapeutics Inc., CYTOKINETICS, Incorporated, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Ferring B.V., Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Par Pharmaceutical by Endo International, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., WellSpring Pharmaceutical Corporation, and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Angiotensin Inhibitors
    • Anticoagulants
    • Antihyperlipidemic
    • Antihypertensive
    • Antiplatelet Drugs
  • Disease Indication
    • Arrhythmia
    • Coronary Artery Disease
    • Hyperlipidaemia
    • Hypertension
  • Route of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Mode of Purchase
    • Over-The-Counter Drugs
    • Prescription-Based Drugs
  • End-Users
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cardiovascular Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiovascular Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Cardiovascular Drugs Market?
  4. What is the market share of the leading vendors in the Cardiovascular Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Cardiovascular Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cardiovascular Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Cardiovascular Disorders
5.1.1.2. Increasing R&D Investments for Drug Development
5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
5.1.2. Restraints
5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
5.1.3. Opportunities
5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
5.1.4. Challenges
5.1.4.1. Complexities in Efficient and Safe Drug Development
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
5.2.2. Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
5.2.3. Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
5.2.4. End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cardiovascular Drugs Market, by Drug Type
6.1. Introduction
6.2. Angiotensin Inhibitors
6.3. Anticoagulants
6.4. Antihyperlipidemic
6.5. Antihypertensive
6.6. Antiplatelet Drugs
7. Cardiovascular Drugs Market, by Disease Indication
7.1. Introduction
7.2. Arrhythmia
7.3. Coronary Artery Disease
7.4. Hyperlipidaemia
7.5. Hypertension
8. Cardiovascular Drugs Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
9. Cardiovascular Drugs Market, by Mode of Purchase
9.1. Introduction
9.2. Over-The-Counter Drugs
9.3. Prescription-Based Drugs
10. Cardiovascular Drugs Market, by End-Users
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Americas Cardiovascular Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Cardiovascular Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Cardiovascular Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. New Product Launch & Enhancement
14.3.1.1. Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India
14.3.2. Investment & Funding
14.3.2.1. Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases
14.3.3. Award, Recognition, & Expansion
14.3.3.1. U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Apotex Inc.
15.1.3. AstraZeneca PLC
15.1.4. Auro Pharma Inc.
15.1.5. Bausch Health Companies Inc.
15.1.6. Baxter International Inc.
15.1.7. Bayer AG
15.1.8. Boehringer Ingelheim GmbH
15.1.9. Bristol-Myers Squibb Company
15.1.10. Chiesi USA, Inc.
15.1.11. Cipla Limited
15.1.12. Cornerstone Therapeutics Inc.
15.1.13. CYTOKINETICS, Incorporated
15.1.14. Daiichi Sankyo Co., Ltd.
15.1.15. Eisai Co., Ltd.
15.1.16. Eli Lilly and Company
15.1.17. F. Hoffmann-La Roche Ltd.
15.1.18. Ferring B.V.
15.1.19. Gilead Sciences, Inc.
15.1.20. Johnson & Johnson Services, Inc.
15.1.21. Merck KGaA
15.1.22. Novartis AG
15.1.23. Novo Nordisk A/S
15.1.24. Otsuka Holdings Co., Ltd.
15.1.25. Par Pharmaceutical by Endo International
15.1.26. Pfizer Inc.
15.1.27. Sanofi S.A.
15.1.28. Teva Pharmaceutical Industries Ltd.
15.1.29. WellSpring Pharmaceutical Corporation
15.1.30. Zydus Group
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. CARDIOVASCULAR DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CARDIOVASCULAR DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CARDIOVASCULAR DRUGS MARKET DYNAMICS
FIGURE 7. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 10. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
FIGURE 14. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 16. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CARDIOVASCULAR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 12. CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 21. CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 24. CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 43. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 47. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 48. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 52. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 70. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 72. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 74. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 75. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 77. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 79. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 85. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 87. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 89. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 115. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 117. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 119. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 133. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 135. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 136. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 138. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 140. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 141. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 143. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 145. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 150. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 155. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 161. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 165. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 176. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 178. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 180. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 181. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 183. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 185. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 186. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 190. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 206. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 210. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 221. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 236. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 237. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 238. CARDIOVASCULAR DRUGS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Apotex Inc.
  • AstraZeneca PLC
  • Auro Pharma Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Chiesi USA, Inc.
  • Cipla Limited
  • Cornerstone Therapeutics Inc.
  • CYTOKINETICS, Incorporated
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Ferring B.V.
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Par Pharmaceutical by Endo International
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • WellSpring Pharmaceutical Corporation
  • Zydus Group

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 90.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 152.61 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Cardiovascular Drugs: Global Strategic Business Report - Product Image

Cardiovascular Drugs: Global Strategic Business Report

  • Report
  • 413 Pages
  • Global
From
Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration (Oral Anticoagulants, Injectable Anticoagulants), By Drug Category, By Application (Atrial fibrillation, Pulmonary embolism), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration (Oral Anticoagulants, Injectable Anticoagulants), By Drug Category, By Application (Atrial fibrillation, Pulmonary embolism), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Global Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Forecast 2024-2030 - Product Image

Global Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Forecast 2024-2030

  • Report
  • 182 Pages
  • Global
From
Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets - Product Image

Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

  • Report
  • 157 Pages
  • Global
From
Anticoagulants Global Market Report 2024 - Product Image

Anticoagulants Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.